Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$1.9 - $8.63 $35,560 - $161,519
18,716 Added 7.49%
268,529 $660,000
Q2 2022

Aug 12, 2022

BUY
$2.13 - $9.01 $31,423 - $132,924
14,753 Added 6.28%
249,813 $609,000
Q1 2022

May 16, 2022

BUY
$6.28 - $15.59 $234,922 - $583,190
37,408 Added 18.93%
235,060 $1.87 Million
Q4 2021

Feb 14, 2022

SELL
$14.7 - $28.67 $61,578 - $120,098
-4,189 Reduced 2.08%
197,652 $3.02 Million
Q3 2021

Nov 15, 2021

BUY
$24.31 - $33.6 $742,451 - $1.03 Million
30,541 Added 17.83%
201,841 $5.74 Million
Q2 2021

Aug 16, 2021

BUY
$26.09 - $40.4 $189,413 - $293,304
7,260 Added 4.43%
171,300 $5.78 Million
Q1 2021

May 14, 2021

SELL
$33.06 - $56.93 $10,546 - $18,160
-319 Reduced 0.19%
164,040 $6.27 Million
Q4 2020

Mar 01, 2021

BUY
$39.09 - $57.4 $859,706 - $1.26 Million
21,993 Added 15.45%
164,359 $6.87 Million
Q3 2020

Nov 13, 2020

BUY
$28.43 - $44.67 $202,791 - $318,631
7,133 Added 5.27%
142,366 $6.17 Million
Q2 2020

Aug 14, 2020

BUY
$11.71 - $30.29 $670,666 - $1.73 Million
57,273 Added 73.46%
135,233 $4.1 Million
Q1 2020

May 15, 2020

SELL
$7.64 - $27.5 $61,311 - $220,687
-8,025 Reduced 9.33%
77,960 $1.07 Million
Q4 2019

Feb 14, 2020

SELL
$15.02 - $20.57 $112,349 - $153,863
-7,480 Reduced 8.0%
85,985 $1.39 Million
Q3 2019

Nov 14, 2019

BUY
$18.85 - $27.5 $562,521 - $820,655
29,842 Added 46.9%
93,465 $1.8 Million
Q2 2019

Aug 15, 2019

BUY
$17.37 - $26.27 $442,969 - $669,937
25,502 Added 66.9%
63,623 $0
Q1 2019

May 14, 2019

BUY
$10.65 - $25.75 $163,445 - $395,185
15,347 Added 67.39%
38,121 $0
Q4 2018

Feb 13, 2019

SELL
$9.26 - $16.38 $88,210 - $156,035
-9,526 Reduced 29.49%
22,774 $251,000
Q2 2018

Aug 14, 2018

BUY
$4.87 - $8.42 $104,705 - $181,030
21,500 Added 199.07%
32,300 $0
Q3 2017

Nov 13, 2017

BUY
$8.89 - $10.4 $96,012 - $112,320
10,800
10,800 $0

Others Institutions Holding NVTA

About Invitae Corp


  • Ticker NVTA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 235,266,000
  • Description
  • Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...
More about NVTA
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.